{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:30:40Z","timestamp":1771475440079,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cllc.2013.12.008","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T13:00:26Z","timestamp":1388754026000},"page":"197-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"15","author":[{"given":"Anne S.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nusrat","family":"Harun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waun Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2013.12.008_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/sonc.2002.30231","article-title":"Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine","volume":"29","author":"Baas","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2013.12.008_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.008_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in\u00a0vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cllc.2013.12.008_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2013.12.008_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","article-title":"PDGF receptors as cancer drug targets","volume":"3","author":"Pietras","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2013.12.008_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1309\/XL6K-8E62-9FLD-V8Q8","article-title":"Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies","volume":"116","author":"Roberts","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cllc.2013.12.008_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/sonc.2002.30234","article-title":"New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents","volume":"29","author":"Nowak","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2013.12.008_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-4781(95)00196-4","article-title":"Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines","volume":"1305","author":"Langerak","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cllc.2013.12.008_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0925-4439(96)00060-9","article-title":"Identification of regulatory sequences in the promoter of the PDGF B-chain gene in malignant mesothelioma cell lines","volume":"1317","author":"Prins","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cllc.2013.12.008_bib10","first-page":"613","article-title":"Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions","volume":"39","author":"Ascoli","year":"1995","journal-title":"Acta Cytol"},{"key":"10.1016\/j.cllc.2013.12.008_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0026-895X(25)09719-6","article-title":"Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme","volume":"46","author":"Dorai","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cllc.2013.12.008_bib12","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib13","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/imammb\/15.1.53","article-title":"Fluid transport in vascularized tumours and metastasis","volume":"15","author":"Sleeman","year":"1998","journal-title":"IMA J Math Appl Med Biol"},{"key":"10.1016\/j.cllc.2013.12.008_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1006\/mvre.1995.1069","article-title":"Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation","volume":"50","author":"Zlotecki","year":"1995","journal-title":"Microvasc Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2013.12.008_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.12.008_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.cllc.2013.12.008_bib20","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1158\/1078-0432.CCR-07-0883","article-title":"Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors","volume":"13","author":"Ali","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2013.12.008_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-09-0650","article-title":"Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions","volume":"16","author":"Behrens","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.008_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jcp.2009.066548","article-title":"EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer","volume":"62","author":"Varella-Garcia","year":"2009","journal-title":"J\u00a0Clin Pathol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730413002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730413002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:03:49Z","timestamp":1761505429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730413002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1525730413002659"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2013.12.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2013.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}